Haemonetics raises 2026 guidance, projects 7%-10% organic growth ex CSL amid strong plasma and hospital performance
Source: SeekingAlpha
2025-11-07 03:27:19 ET
More on Haemonetics
- Haemonetics Corporation (HAE) Q2 2026 Earnings Call Transcript
- I'm Recommending Haemonetics Again, But With Caveats (Ratings Upgrade)
- Haemonetics Corporation (HAE) Q1 2026 Earnings Call Transcript
- Haemonetics Q2 2026 Earnings Preview
- Seeking Alpha’s Quant Rating on Haemonetics
Read the full article on Seeking Alpha
For further details see:
Haemonetics raises 2026 guidance, projects 7%–10% organic growth ex CSL amid strong plasma and hospital performance
Haemonetics Corporation
NASDAQ: HAE
HAE Trading
0.13% G/L:
$59.65 Last:
182,586 Volume:
$60.29 Open:
HAE Latest News
February 23, 2026 04:15:00 pm
Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
February 20, 2026 04:05:00 pm
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference
HAE Stock Data
$2,748,315,639
45,616,277
0.08%
124
N/A
Medical Equipment & Supplies
Healthcare
US
Boston
